Cargando…
Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer
PURPOSE: Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) to inhibit tumor growth. Nimotuzumab has demonstrated desirable therapeutic activity in various types of tumors. However, the benefit of nimotuzumab for the treatment of cervical cancer i...
Autores principales: | Chen, Wenli, Li, Tao, Wang, Jian, Liang, Long, Huang, Dandan, Yan, Gaoshu, Tian, Ye, Zhang, Xiaoli, Zhang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731987/ https://www.ncbi.nlm.nih.gov/pubmed/31564975 http://dx.doi.org/10.2147/CMAR.S191134 |
Ejemplares similares
-
Efficacy and safety of nimotuzumab combined with chemoradiotherapy in the treatment of locally advanced cervical cancer
por: Zhang, Lei, et al.
Publicado: (2022) -
Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis
por: Liu, Zhi-gang, et al.
Publicado: (2016) -
Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma
por: Wang, Lili, et al.
Publicado: (2023) -
Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma
por: Li, Zhanzhan, et al.
Publicado: (2017) -
Surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer
por: Zhang, Xiang, et al.
Publicado: (2021)